Clinical Trial

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific...

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Results highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth...

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

The first two Fanconi Anemia patients receiving JSP191 achieved 100% donor chimerism JSP191 safe to infuse with no treatment-adverse events...

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting

Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLESOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE...

SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a...

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

Understanding Hunger & Bardet-Biedl Syndrome (BBS): Gabe’s Story Developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation-- Book developed in...

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting

HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuriesDURHAM, N.C., Sept. 23, 2022 (GLOBE...

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia,...

error: Content is protected !!